New research published in JMIR Diabetes demonstrated the real-world effectiveness of the Fitterfly Diabetes digital therapeutic program.
The Fitterfly Diabetes CGM digital therapeutic aims to help in the management of glycemic control for people with type 2 diabetes. Led by Shilpa Joshi, Arbinder Singal, and colleagues, the study demonstrated significant improvements in blood glucose levels and weight management. It evaluated participants throughout a 90-day program.
Delivered through the Fitterfly mobile app, the program couples with continuous glucose monitoring (CGM) technology. It offers tailored recommendations on nutrition-based, personalized glycemic response data, exercise and behavior modifications. The program aims to give individuals the tools they need to manage their condition and make long-term lifestyle changes to support health.
Results of the Fitterfly study
According to a news release, the study analyzed de-identified data of 109 participants with type 2 diabetes. The program features three phases. First, it observes participants’ CGM readings for one week. Next, they received diet- and exercise-based interventions through the Fitterfly app and coaches. Finally, researchers tracked whether the participants sustained their new lifestyle modifications over three months.
Researchers say about 85% of all participants observed an average reduction of 1.2% in HbA1c levels. The reduction came in even higher (2.6%) for participants who began the program with an HbA1c above 9%. Study participants also lost an average of 2.05 kg body weight, and their BMI reduced by 0.74 kg/m2.
The study also found that participants who engaged more with the Fitterfly app presented improved clinical outcomes.
“Type 2 diabetes is a huge health care concern in India. With the use of newer tools such as digital therapeutics now getting adopted by people and enterprise partners, and getting prescribed by physicians, we are bridging the gap for behavior change,” said Arbinder Singal, Fitterfly CEO and co-founder. “The study affirms our belief that digital therapeutic programs can provide clinically validated outcomes and help the population at scale.”